Xeljanz Development Plans Scaled Back By Pfizer
This article was originally published in Scrip
You may also be interested in...
Ex-Pfizer Employee Overseeing Xeljanz Global Marketing Sued For Trade Secret Theft
Pfizer says its former global marketing director emailed and copied hundreds of documents on product launch plans and steps to obtain government approvals before leaving the company in January.
Pfizer Assembling New Commercial Team For Move Into Dermatology
The big pharma is moving into a new therapy area – dermatology – as part of a three-pronged strategy in Inflammation & Immunology that also includes rheumatology and gastroenterology. Pfizer’s first product for dermatology, crisaborole for atopic dermatitis, could launch next year.
First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.